Table of Contents
ISRN Oncology
Volume 2012, Article ID 478607, 6 pages
http://dx.doi.org/10.5402/2012/478607
Review Article

Proof of Concept to Clinical Confirmation: Evolving Clinical Trial Designs for Targeted Agents

Hematology/Oncology, Mayo Clinic Florida, Jacksonville, FL 32224, USA

Received 4 January 2012; Accepted 12 February 2012

Academic Editors: M. Amichetti, N. A. Franken, and M. Loizidou

Copyright © 2012 Laura Finn and Winston Tan. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

No single therapy benefits the majority of patients in the practice of oncology as responses differ even among patients with similar tumor types. The variety of response to therapy witnessed while treating our patients supports the concept of personalized medicine using patients' genomic and biologic information and their clinical characteristics to make informed decisions about their treatment. Personalized medicine relies on identification and confirmation of biologic targets and development of agents to target them. These targeted agents tend to focus on subsets of patients and provide improved clinical outcomes. The continued success of personalized medicine will depend on the expedited development of new agents from proof of concept to confirmation of clinical efficacy.